These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1929760)

  • 61. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
    Chou JC; Douyon R; Czobor P; Volavka J; Cooper TB
    Psychiatry Res; 1998 Oct; 81(1):51-5. PubMed ID: 9829650
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
    Andia I; Zumarraga M; Zabalo MJ; Bulbena A; Davila R
    Biol Psychiatry; 1998 Jan; 43(1):20-3. PubMed ID: 9442340
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 72. Plasma homovanillic acid concentration and the severity of schizophrenic illness.
    Davis KL; Davidson M; Mohs RC; Kendler KS; Davis BM; Johns CA; DeNigris Y; Horvath TB
    Science; 1985 Mar; 227(4694):1601-2. PubMed ID: 3975630
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clozapine response and plasma catecholamines and their metabolites.
    Green AI; Alam MY; Sobieraj JT; Pappalardo KM; Waternaux C; Salzman C; Schatzberg AF; Schildkraut JJ
    Psychiatry Res; 1993 Feb; 46(2):139-49. PubMed ID: 8483973
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Morning variations of plasma homovanillic acid in untreated schizophrenic patients.
    Zumárraga M; Andía I; Bárcena B; González-Torres MA; Dávila R
    J Psychiatr Res; 1993; 27(1):11-6. PubMed ID: 8515382
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Free and conjugated plasma homovanillic acid in schizophrenic patients.
    Garcia A; Galinowski A; Guicheney P; Mignot E; Loo H; Meyer P
    Biol Psychiatry; 1989 May; 26(1):87-96. PubMed ID: 2720023
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR; Labarca R; Wolkowitz OM; Roy A; Douillet P; Pickar D
    Arch Gen Psychiatry; 1990 Jun; 47(6):558-63. PubMed ID: 2350208
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.